NPG: Thank you for joining us. It's nearly 20 years since you published your first gene therapy paper. Verma: Yes, in 1983 and we published with Ted Friedmann, Doug Jolly -then a student with Ted -and Dusty Miller, a postdoc fellow in my lab and now a well-established figure in the field of gene therapy. The experiment was the following: in my lab, we were interested, in general, in how retroviruses grow, how they infect cells and cause leukaemia. When we looked at the genome, we found that some of them had a defect where they couldn't replicate. Instead of replicating they acquired a sequence called an oncogene and as such can actually cause transformation and cancer of the cells. So we argued that there are two kinds of viruses: viruses that can grow and cause cancer and then viruses that are defective for replication but could cause cancer by acquisition of cellular sequences.
We argued that if they can acquire cellular sequences and cause cancer, why can't we substitute the cancer gene with a gene of interest? The gene of interest we had was called HPRT, which, when missing, causes a disease called Lesch-Nyhan syndrome. Dusty Miller asked a very simple question: if we take the defective retrovirus and substitute the oncogene with HPRT and infect the deficient cells with the recombinant retrovirus, do they now have the ability to make HPRT? And the answer was yes, and that really was the beginning of saying:
why can't we use viruses as a way of delivering genes into cells missing a product? NPG: And then? Verma: It became very clear that that particular way was good to show the proof of principle, but we didn't want to have viruses that replicate, because that will cause cancer. So we and others started to ask if we can take viral RNA, remove the sequences involved in its packaging and still maintain its ability to make the protein that we are interested in.
Richard Mulligan, Richard Mann, a graduate student with David Baltimore, who was then at MIT, removed a sequence known to be necessary for viral packaging. That started the idea that we could use retroviruses as a way of delivering genes, because with the packaging sequence removed, infectious virus particles will not be formed; proviral DNA will be formed that can integrate and only produce the protein of interest. So that really is the genesis of retroviral vectors. NPG: And how did you feel when you did that first experiment? Verma: When we did our first HPRT experiment of course we were younger so we were much more excitable, and our paper was picked up by Reuter and the New York Times. We always thought New York Times was for famous people, and there it was on the front page saying 'Scientists deliver genes'. So it was quite exciting. We felt that we could do anything -we thought we could take any gene and put it back into the animal.
I don't think it was a historic event, but I think that was the beginning of at least retroviral vectors, which preceded most other vectors in terms of the timeline. NPG: What would you say has given you your greatest sense of triumph? Verma: I won't use the word 'triumph', that sounds so pompous! Two things: One was the idea that you could use disease-causing viruses as a useful entity. That was very exciting.
The second exciting part was that people could actually begin to use these much more in biological experiments than in gene therapy. Suddenly, everybody needed a tool to introduce genes in cells, tissues, organs, whole animals, and this was a tool to do that. It was very exciting because it actually became a much more popular tool in biology than in gene therapy.
And then it became very clear that what we really wanted to do was to use the genes to correct genetic diseases in humans, starting with animals as models. And that's where we hit the first roadblock. We took fibroblasts from a mouse, introduced a retrovirus to make Factor IX, put it back into the animal, and for 10 days it made the protein. Then suddenly the protein shut off. We did the same experiment in tissue culture and found it kept producing the protein for years. So that was the first big surprise: how come retroviruses, which are able to produce the protein in a tissue culture, when put into the cell and the cells put back into the animal, completely shut off production of the foreign protein? It became very clear it was because retroviruses can only transduce genes in cells that are dividing. And we had to take cells out to divide them to introduce the genes, and when we put them back there was a complete shut-off of transcription. That was a big surprise for everybody and I would call that one of the low times for us. We were really hot on it and suddenly it didn't work. And then we went into muscles and it still didn't work, and then we went into the dog and it still didn't work and around 1988-1989 we had to really rethink our strategy. We can't use retroviruses to introduce genes in nondividing cells. The lung doesn't divide; the liver doesn't divide; the brain doesn't divide. There was no way we could take cells out, transduce them and put them back. We had to think of a new strategy. NPG: So you would say this was the first disappointment? Verma: That was the first. So then the adenoviruses came -everywhere was 'adeno'. You couldn't open a journal without a blue lung, a blue liver, a blue heart -we were at the 'blue period' of gene therapy! We put it in a mouse defective for Factor IX and were very successful, but it turned out that if you took a normal mouse with a competent immune system, there was absolutely no production after a few days. And suddenly the whole thing came crashing home: adenoviruses are terrific vectors to make lots of protein from introduced genes in dividing and nondividing cells, but they have serious immunological consequences. We began to think, maybe it's because we don't know how to make vectors. Tal Kafri, a postdoctoral fellow, finally did a very simple experiment: he took adenoviruses, deactivated them and put them back into the animal, but we found as much problem with the immune system as with a live virus.
That showed us that the incoming viral proteins are presented in the cell as foreign and cytotoxic T cells generated against those proteins kills those cells. Therefore, adeno is a great tool for producing protein for a few days, for example, to kill a tumour cell, but for sustained production of a foreign protein it's really tough. So that was a general set back to the field.
Then came the AAV vectors around 1990, which could do many of the things the adenoviruses could do, but the problem we encountered very soon was that they had a very limited size. You could only put in genes of about 3 or 4 kb and you could put no promoters with it. And more importantly, because they didn't integrate well, you couldn't use them in stem cells. We took blood stem cells and put AAV in them. First, it didn't infect them and second, every time they divided you lost the AAV.
So around 1995 or so we were stuck. We asked what we would like if the world was all in our hands. We wanted something that we can make lots of -if you don't make millions of recombinant viral particles, how do you introduce the gene in the brain, which is a trillion cells, or in the liver, which is billion cells? You want something that will introduce genes in dividing cells -cancer cells -and nondividing cells, like a neuron or liver or lung cells.
We wanted something whose integration we could control. The genome is 3 billion bases, 20-30 thousand genes, so we wanted to be able to introduce the gene where we wanted, to know whether it's safe or not.
We wanted something we could control the protein production like of a homeostat, turn it on, off, when, where, how much.
We wanted the ability to infect any cell type and we wanted no unpleasant immunological results.
We wanted something like an adenovirus, which can introduce genes in nondividing cells, and yet have no immunological consequences. We wanted it to behave like a retrovirus to integrate in the chromosome and yet be able to introduce genes in a nondividing cell. This is where HIV -a member of the retro family -turned out to have all the properties of a retrovirus but with the additional property that it can introduce genes in nondividing cells.
We teamed up with Didier Trono who was an assistant professor then at The Salk Institute, and Luigi Naldini, who had just come as a postdoc in my lab at that time. Immediately two problems occurred. First, HIV infects CD4+ cells, which is usually on very few cell types. We had no intention to make a vector that is so restricted. The first thing we did was to eliminate the envelope protein of HIV, GP120, which allowed it to be pantropic and not restricted to just to CD4+ cells. That was the first victory we had, borrowed on other people's work.
The second victory was to ask how we could make it a safe vector. Can we eliminate all seven accessory genes that cause the disease, and still maintain the ability to introduce the genes in nondividing cells? We were fortunate again: we could eliminate all of them. What had taken us years now took days because we had fundamental knowledge from our group and from hundreds of other people who had done it, and very quickly generated a third generation vector, which had the ability to introduce genes in any cell type, efficiently.
In terms of our original wish list, we could now make billions of particles. We could infect dividing and nondividing cells. We could even regulate the production of the foreign protein like a homeostat, but what we didn't have was the ability to control where it goes in the chromosome. That is a problem you have with all viral vectors that integrate and we don't know how to solve it. Of course the findings of the French group actually showed that retroviruses cause cancer by insertional mutagenesis, the way we always worried it would. Lentiviruses may offer some advantages because they have certain modifications but it remains a concern that we don't know how to control the integration site. And that is a bigger problem when you're talking about a stem cell, because stem cells will amplify. If the gene went in a bad site in day 1, everything that comes from that will be in the bad site.
In somatic tissue, I worry less. If it went into the brain and it integrated next to, say, a suppressor gene, it is unlikely to make a tumour because it is one cell in the background of billions. Furthermore, what really convinced me to be less concerned at that time was AIDS patients. They have 1 Â 10 15 infections and they have so much virus that when you give them a drug, it's completely inhibited; you remove the drug and in 1 week the virus comes fulminating millions of copies of it. That means the virus is sitting there, in the chromosome, hidden, integrated, and yet no one to date has ever found a tumour that is due to HIV integration.
That to me was a very interesting corollary: why is it that HIV affects so abundantly, with so much reproduction of the virus, yet viral integration produces no tumours. There may be something unique about this but there is still the concern of HIV vector: we don't know how to control the site of integration. NPG: Just sorting out the basic challenges of the vectors at the moment is the current challenge? Verma: I leave my audiences with four challenges. The first is that we still need to make lots of good viral vectors. We don't know enough about them. We need to have very good virologists around us and we don't have enough.
We still need very good molecular biologists, to tell us much more about regulation and integrationwe don't know anything about regulation really. We need a much better handle on promoters.
The big problem of gene therapy will be immunology. We don't know whether the vector is immunogenic, or more importantly, whether the transgene is immunogenic. If the patient has never seen the transgene, what is going to happen? And even more complicated in my mind is, what happens to the cells that have suddenly got 100 000 AAV or Adeno particles? Suddenly the nucleus, which usually has 6 pg of DNA has a thousand copies of new DNAwhat's it going to do? Is the nucleus going to bulge out, break up? That will remain a concern.
And finally, the stem cell biology. With integrated stem cells, it could be a problem if the gene integrated inadvertently. On the other hand, with stem cells, you only need 10 to make a whole tissue rather than trying to put genes in an entire liver and so on.
So you need virology, molecular biology, immunology and cell biology to really have a successful modality of gene therapy. And then it has to go to the clinicians, and the clinicians have to come back and tell us if a vector isn't working. That aspect has to go on, back and forth. NPG: I wanted to ask about the interdisciplinary nature of the field of gene therapy. Do you think that's something that should increase? Verma: Yes and in fact I think there are ways to do it. There are program projects to promote interaction between these people. However, each one of them can only make limited contributions. For example, I work on AAV but I don't make any contribution to the improvement of AAV as a vector, because that is not my strength. So you need two kinds of people: those who make the improvements, and those who use the vectors. The guy who wants to do gene therapy for humans doesn't care who makes the vector -he's interested in its function.
People have to see that while there is considerable glory in doing clinical trials there is an interesting lesson in the example of haemophilia B trials. They were safety trials, never enough AAV vector was injected to make sufficient therapeutic protein, yet the undertaking of the very trial made news, patients were hopeful, yet after a while the muscle trial was abandoned having achieved its goals of showing safety. Nobody asked who had contributed to generation of AAV vectors as a way of gene delivery. There was no mention of folks like Jude, Nick and Barry who really made seminal discovery of making AAV into vectors. There is a certain allure of treating patients because that's what the newspapers pick up and that's where the excitement is. However, the clinicians have to come back to the bench scientists and say, guys, you screwed up, this is not the right vector! NPG: So you think there's not enough communication going back? Verma: There has to be more, I think. More back and forth. That hasn't happened as much as I would have liked to have seen. However, that doesn't mean people aren't aware of it, I just think that's an important complement of successful gene therapy. NPG: Do you think people identify themselves as 'gene therapists' or do you think they would say they were virologists, etc? Verma: It's funny because it's almost a jargon now -no one refers to themself as 'gene therapyologist'. I refer to myself as someone who works on gene delivery vectors. I truly do not work on diseases, because I am not a clinician: I haven't the faintest idea where the gall bladder isy 70% of gene therapy in clinics is cancer. All the rest of it is only 30%. NPG: Do you think that's where the greatest success will come? Verma: No, not necessarily, I just think those are patients who have no alternative treatment; they are often terminal. I think successes will come with the metabolic diseases; you will see the effect immediately with haemophilia; you will see the effect in diabetes. They haven't worked now but you are likely to see a directly proportional effect there. Whereas, in cancer, a lot is still unknown. You put in a vaccine, it will work; nobody quite knows exactly how, whereas with metabolic diseases you know. A protein is missing, you put it in, it comes back -and now that must function. NPG: So which do you think are going to be the most promising target diseases? Verma: I personally think the brain will be a big opportunity, because it's limited in size and it's restricted where you can do it. I would say gene therapy will have a very big impact on diseases like Parkinson's. I do not understand for the life of me why haemophilia hasn't worked better; I do not understand that at all. And there is still more interesting stuff to come from stem cell diseases, like SCID -that is a successful story. It's hard to know, but those are the areas I think a lot of success will come. NPG: Do you think funding is going in a particular direction? Verma: The commercial companies have considerably reduced their funding in gene therapy areas. I know of no major pharmaceutical companies that invest in gene therapy. There are hardly half a dozen gene therapy companies that are left. A company like Cell Genesys, of which I am a founder, board member, chair of the scientific advisory board, is doing cancer gene therapyit's not even gene therapy, it's cancer therapy. By and large, that aspect of the money has died and everybody wants to do phase 1 and 2 clinical trials. No one wants to invest in a company researching gene delivery vectors. I would say still that the primary source is private foundations. Glorioso: It may turn out like a few years ago, in the pharmaceutical industry, when vaccines were very low priority. They were too dangerous, they had too many adverse effects, there wasn't enough money per dose, and so on. And now there has been a huge resurgence, for a number of reasons. Verma: An equally good analogy could be monoclonal antibodies. They were dying and then they came back. Don't think I'm being a proselytiser, but I believe gene therapy is the only modality of medicine that has influence in every aspect of human disease. Heart, lung, muscle, brain, infectious -every aspect of human disease can be influenced if we know how to efficiently and safely introduce a gene. NPG: You have hope for everything, rather than just for rare diseases? Verma: It will affect everything, any disease. Every disease has a genetic component. And what we are saying is that we would modify their genetics to remove that component. It's just a matter of learning the technology. Therefore, I think funding and looking for vectors and ways to do it is highly justified because there is no other technology in the world for every aspect of human health. NPG: It's optimistic in a long-term sense?
Verma: Absolutely, there is no other way in the long run. We'll keep on making small molecules but if we can actually make the normal protein to replace the defective or offending protein, it will be a tremendous boon. Glorioso: Why would you use gene therapy versus protein or drug therapy? One of the obvious things that comes to mind is local delivery and expression. Verma: Absolutely, and second, the cost. And third, imagine with Factor IX -there's a wonderful new protein, but you've got to inject it every day. You take a 4-year-old kid: he has to carry a little syringe so that if he goes to play for the next week someplace, he has to inject himself, all the time. We are offering a possibility that once we have introduced the gene, the child will be no different than other children with the normal gene. That is a powerful motivation. For gene therapy also, there is a quality of life improvement, not just longevity, but quality of life improvement. NPG: What's your biggest hope for the future? Verma: I think gene therapy will work. I may get even greyer, but it certainly will work. Glorioso: When did you first hear the words 'gene therapy'? Can you recall that? Verma: You know, I don't remember that. It could have been the early 70s or early 80s. I actually, honestly, pay little attention to these things. There was an article in Science in the 70s I think, but I don't remember. I would say early 80s -1981, 1982 -when I got involved in it. Glorioso: In the early 80s, was that one of the first national meetings?
Verma: I organised the first major meeting on gene transfer in 1983 in Granlibaken as part of UCLA -ICN winter symposium. I did it with Richard Mulligan and Art Beaudet in 1983 and we asked where gene therapy was going and what the important elements were and how we were going to do it. I still think it's exciting but it really is important to note that this technology has done wonders, not only for medicine, but also for biology. I bet every third paper in Cell, Science or Nature has a delivery system to do that experiment. siRNA is probably the next big thing after PCR in my mind, and how are they going to deliver the siRNA? They're not going to shoot them with big needles under high pressure into someone's liver without vectors. So delivery will be for every new technology of biology. NPG: Thank you very much.
